Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | H4279 | SC |
she gave 0.5 mL subcutaneously instead of IM; he gave 0.5 mL subcutaneously instead of IM, she gave it in the forearm; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a 20-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number H4279, expiry date 30-AUG-2027) for prophylaxis. On 15-JUL-2025, the patient received Boostrix (subcutaneous, unknown arm) .5 ml. On 15-JUL-2025, an unknown time after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: she gave 0.5 mL subcutaneously instead of IM) and vaccine administered at inappropriate site (Verbatim: he gave 0.5 mL subcutaneously instead of IM, she gave it in the forearm). The outcome of the intramuscular formulation administered by other route and vaccine administered at inappropriate site were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-JUL-2025 Practice manager reported that called because one of the nurses made an error while giving immunizations, that involved the Boostrix. Reporter mentioned what happened if that she gave the Boostrix 0.5 ml subcutaneously instead of intramuscularly, she gave it in the forearm, which led to intramuscular formulation administered by other route and vaccine administered at inappropriate site. So, reporter wanted to see potential, if being in a different location and potential for anything. The reporter said that to the second line agent that he did not give the complete dose, only 0.5, however according to package insert was the recommended dose.